Jianxin Lin

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Kevin J. Harrington, Barbara Burtness, Richard Greil et al. · Journal of Clinical Oncology · 2022 · 490 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Class II Major Histocompatibility Complex Plays an Essential Role in Obesity-Induced Adipose Inflammation

Tuo Deng, Christopher J. Lyon, Laurie J. Minze et al. · Cell Metabolism · 2013 · 373 citations · Full text

Life Sciences, Immunology, Physiology +14

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee et al. · Blood · 2019 · 329 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Gilberto de Castro, Iveta Kudaba, Yi‐Long Wu et al. · Journal of Clinical Oncology · 2022 · 318 citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Hossein Borghaei, Corey J. Langer, Luis Paz‐Ares et al. · Cancer · 2020 · 111 citations · Full text

Medicine, Oncology, Pharmacology +17